ライフサイエンスコーパス: exenatide

1 tion-to-treat analysis (450 liraglutide, 461 exenatide).

2 tion-to-treat analysis (450 liraglutide, 461 exenatide).

3 (semaglutide), and EXSCEL (extended-release exenatide).

4 -1R agonists (liraglutide, lixisenatide, and exenatide).

5 in systolic blood pressure was observed with exenatide.

6 sensor in the porto-hepatic circulation with exenatide.

7 ht and body mass index than those not taking exenatide.

8 ced risks were predicted for weight loss and exenatide.

9 raglutide, semaglutide, and extended-release exenatide.

10 roup (adjusted coefficient for the effect of exenatide 0.92 [95% CI -1.56 to 3.39]; p=0.47).

11 male Sprague Dawley rats were injected with exenatide (0.1, 0.5, 5 and 10 microg/kg) or saline intra

12 ts per patient per year) than in those given exenatide (0.3 events per patient per year).

13 mia less frequent with liraglutide than with exenatide (1.93 vs 2.60 events per patient per year; rat

14 ced mean HbA(1c) significantly more than did exenatide (-1.12% [SE 0.08] vs -0.79% [0.08]; estimated

15 ed mean fasting plasma glucose more than did exenatide (-1.61 mmol/L [SE 0.20] vs -0.60 mmol/L [0.20]

16 nal liraglutide 1.8 mg once a day (n=233) or exenatide 10 microg twice a day (n=231) in a 26-week ope

17 bA1c 5.76%) were assigned (1:1) to diet with exenatide 10 mug twice daily treatment (n = 15) or witho

18 equence interactive voice-response system to exenatide, 10 microg twice daily, or placebo for 30 week

19 Sixteen subjects commenced exenatide, 12 continue (follow-up 214+/-57 days; range 1

20 y approximately 20% (saline 13.2 +/- 1.9 vs. exenatide 15.6 +/- 2.1 mg x kg(-1) x min(-1), P < 0.05)

21 d in the intention-to-treat analysis (160 on exenatide, 166 on sitagliptin, and 165 on pioglitazone).

22 atients were assigned to receive once weekly exenatide, 172 to receive sitagliptin, and 172 to receiv

23 web-response system, to receive once-weekly exenatide 2 mg by subcutaneous injection plus once-daily

24 e and study site to receive extended-release exenatide 2 mg by subcutaneous pen injection once per we

25 (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in ad

26 Lowering) assessed the impact of once-weekly exenatide 2 mg versus placebo in patients with type 2 di

27 (1:1) to receive subcutaneous injections of exenatide 2 mg weekly for 48 weeks, or as controls, foll

28 espite hyperglycemia (saline 2.9 +/- 0.6 vs. exenatide 2.3 +/- 0.3 mg x kg(-1) x min(-1), P = 0.29).

29 ntry and concomitant therapy) to once-weekly exenatide (2 mg subcutaneous injection) or once-daily gl

30 ce-daily liraglutide (1.8 mg) or once-weekly exenatide (2 mg).

31 Weight loss with exenatide (-2.3 kg, 95% CI-2.9 to -1.7) was significantl

32 milar weight losses (liraglutide -3.24 kg vs exenatide -2.87 kg).

33 ucose infusion rate (saline 15.9 +/- 1.6 vs. exenatide 20.4 +/- 2.1 mg x kg(-1) x min(-1), P < 0.001)

34 dial hyperinsulinemia and hyperglycemia with exenatide (20 microg) or saline injected at 0 min.

35 ast one dose of the assigned drug (233 given exenatide, 223 glargine).

36 ticipants, more frequently with placebo than exenatide (38.1% versus 28.8%), with metformin (6.1% ver

37 mg/dL, and 2-h glucose of 177 +/- 11 mg/dL, exenatide (5 mug) or placebo was injected in double-blin

38 ts with type 2 diabetes received intravenous exenatide (7.5 mug) or saline (-30 to 240 min) in a doub

39 Exenatide significantly lowered ICP [exenatide: 9.74 (6.09) mmHg, n = 19, vehicle: 18.27 (6.6

40 EXSCEL evaluated the effects of once-weekly exenatide (a GLP-1 [glucagon-like peptide-1] receptor ag

41 etrant, pegylated, longer-lasting version of exenatide (a glucagon-like peptide-1 receptor agonist) t

42 , double-blind trial to assess the effect of exenatide, a GLP-1 receptor agonist, on intracranial pre

43 essed the safety and efficacy of once weekly exenatide, a glucagon-like peptide 1 receptor agonist, v

44 Exenatide, a glucagon-like peptide-1 (GLP-1) receptor ag

45 Exenatide, a glucagon-like peptide-1 (GLP-1) receptor ag

46 tion, whether the cardioprotective effect of exenatide, a glucose-lowering drug, is dependent on hype

47 Recent progress suggests that exenatide, a mimetic of glucagon-like peptide-1 (GLP-1),

48 formulations with and without encapsulating exenatide, a pH-labile peptide that is known to be unsta

49 Exenatide, a promising cardioprotective agent, protects

50 The interactions of exenatide, a Trp-containing peptide used as a drug to tr

51 Compound 10 is composed of an exenatide (AC2993) analogue, AC3174, and an amylinomimet

52 eutic polypeptides; insulin, calcitonin, and exenatide across the monolayer.

53 The GLP-1 receptor agonist exenatide activated SERCA but did not alter other Ca(2+)

54 intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to

55 The coprimary hypotheses were that exenatide, administered once weekly, would be noninferio

56 Our results show that the net cationic exenatide adsorbs electrostatically to liposomes contain

57 Whether exenatide affects the underlying disease pathophysiology

58 Subjects on exenatide after ITx showed significantly lower weight an

59 HbA1c from baseline to week 28 compared with exenatide alone (-0.4% [95% CI -0.6 to -0.1]; p=0.004) o

60 eceive exenatide plus dapagliflozin (n=231), exenatide alone (n=231; n=1 untreated), or dapagliflozin

61 Incubation with exenatide also inhibited thrombus formation under flow c

62 Exenatide also reduced some postprandial CERs, PCs, and

63 Exenatide also reversibly inhibited I(Nav1.5) with IC(50

64 rt, were prevented by exposure to exendin-4 (exenatide), an anti-diabetes agent.

65 of liraglutide, a human GLP-1 analogue, with exenatide, an exendin-based GLP-1 receptor agonist.

66 The HbA(c) level decreased by 1.74% with exenatide and 1.04% with placebo (between-group differen

67 s were enrolled and randomly assigned, 32 to exenatide and 30 to placebo.

68 Two patients taking both exenatide and a sulphonylurea had a major hypoglycaemic

69 -0.4% [95% CI, -0.7% to -0.2%]), once-weekly exenatide and albiglutide for fasting plasma glucose (-0

70 Co-initiation of exenatide and dapagliflozin improved various glycaemic m

71 risk, and to assess the interaction between exenatide and hyperglycemia.

72 Weight decreased by 1.8 kg with exenatide and increased by 1.0 kg with placebo (between-

73 Glucagon-like peptide-1 receptor agonists exenatide and liraglutide have been shown to improve gly

74 reated for 1 year with GLP-1R agonists, both exenatide and liraglutide increased energy expenditure.

75 Average increases in insulin dosage with exenatide and placebo were 13 U/d and 20 U/d.

76 Exenatide and sitagliptin treatments have led to a lower

77 The most frequent adverse events with exenatide and sitagliptin were nausea (n=38, 24%, and n=

78 gon-like peptide-1 receptor (GLP-1R) agonist exenatide and the calcitonin gene-related peptide recept

79 co-initiation of the GLP-1 receptor agonist exenatide and the SGLT2 inhibitor dapagliflozin with exe

80 significantly between patients who received exenatide and those who received placebo.

81 empagliflozin, liraglutide, extended-release exenatide, and dapagliflozin reduced all-cause mortality

82 ma glucose; taspoglutide, 20 mg, once-weekly exenatide, and dulaglutide, 1.5 mg, reduced body weight.

83 y GLP-1RAs, dulaglutide, 1.5 mg; once-weekly exenatide; and taspoglutide, 20 mg, showed a greater red

84 We found no evidence to support exenatide as a disease-modifying treatment for people wi

85 orted among patients who took sitagliptin or exenatide as compared with other therapies (P<.008, P<9x

86 nts for insulin resistance (pioglitazone and exenatide) as possible disease modifying drugs in Parkin

87 ents were fewer, and transit was slower with exenatide, as were the areas under the curves for serum

88 subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once wee

89 In conclusion, exenatide augmented postprandial EF in subjects with dia

90 by right censoring, but the favorable HR for exenatide became nominally significant in the sulfonylur

91 Nausea was greater in both groups with exenatide, but suppression of small intestinal motility

92 rst, generated steady-state plasma levels of Exenatide, but with PT320 producing continuous therapeut

93 They were administered 17.4 mug exenatide (Byetta) or placebo over a 6-hour and 15-minut

94 peptide templates, such as the diabetes drug exenatide (Byetta).

95 he glucagon-like peptide-1 receptor agonist, exenatide (Byetta, Amylin Pharmaceuticals, CA) has prope

96 nction represents a novel mechanism by which exenatide can attenuate postprandial glycemia.

97 ls in vivo, glucose tolerance after an acute exenatide challenge was improved.

98 During fasting, exenatide, compared with control, reduced some ceramides

99 d all cancers associated with sitagliptin or exenatide, compared with other therapies.

100 uated from the area under the time-dependent Exenatide concentration curve, was similar for equivalen

101 cal utility is illustrated by a PEG hydrogel-exenatide conjugate that should allow once-a-month admin

102 stablish whether the GLP-1 receptor agonist, exenatide, could slow the rate of progression of Parkins

103 her reduced in those initially randomized to exenatide (cumulative BMI reduction of 4%).

104 Exenatide did not reduce neuron-specific enolase levels

105 Exenatide directly stimulates glucose turnover by enhanc

106 ated to liraglutide and 12 (3%) allocated to exenatide discontinued participation because of adverse

107 Here, we explored whether exenatide displayed anti-AF effects by inhibiting human

108 Furthermore, the GLP-1 receptor agonist, Exenatide, dose-dependently enhanced phosphorylation of

109 efficacy of an infusion of the GLP-1 agonist exenatide during and after open-heart surgery in reducin

110 Exenatide during cardiopulmonary bypass and weaning ther

111 als with induced periodontitis that received exenatide (EG); 2) animals with induced periodontitis th

112 Incubation with GLP-1 and the GLP-1R agonist exenatide elicited a cAMP response in MEG-01 cells, and

113 Exenatide elicited a greater reduction in percent change

114 Exenatide elicited eNOS activation and NO production in

115 Once-weekly exenatide (EQW) had a neutral effect on hospitalization

116 gon-like peptide receptor agonist (GLP-1 RA) exenatide (EQW) vs. placebo.

117 Thus, we evaluated the acute effects of exenatide (EX) on hepatic (Hep-IR) and adipose (Adipo-IR

118 Exenatide (Ex4), a GLP-1 incretin mimetic polypeptide, i

119 s study, we aimed to evaluate the effects of exenatide (EXE) treatment on exocrine pancreas of nonhum

120 In this study, we investigated the effect of exenatide (EXE), a glucagon-like peptide (GLP)-1 recepto

121 raftment and long-term graft function of SI, exenatide (EXN) and etanercept treatment at islet infusi

122 a profile of PT320, a sustained-release (SR)-Exenatide formulation under clinical development for tre

123 Both SR-Exenatide formulations proved well-tolerated and, follow

124 ents initiating liraglutide, dulaglutide, or exenatide from January 1, 2015, to December 31, 2021, an

125 ptin and the glucagon-like peptide-1 mimetic exenatide, from 2004-2009; data on adverse events associ

126 of this study is to evaluate the effects of exenatide (GLP-1 agonist) and sitagliptin (DPP-4 inhibit

127 Based on data on XTEN fusions to exenatide, glucagon, GFP and human growth hormone, we ex

128 with saline (-14.0-[-16.7]%) to -16.6% with exenatide:glucagon (-14.1-[-17.6]%), n = 8, z=-1.54, r=-

129 f 0.9% saline, glucagon (12.5 ng/kg/min) and exenatide:glucagon co-infusion (exenatide loading dose 5

130 Exenatide:glucagon significantly increased the median le

131 umol/g/min (5.4-98 x 10(-3) umol/g/min) with exenatide:glucagon, n = 8, z = 2.24, r = 0.79, P < 0.05.

132 -1.48%, SE 0.05; n=386) than in those in the exenatide group (-1.28%, 0.05; 390) with the treatment d

133 s who reported serious adverse events in the exenatide group (36 patients [15%]) was the same as that

134 x; 2.5-8.3 years), 170 (24%) patients in the exenatide group and 165 (24%) patients experienced a pri

135 primary analysis included 31 patients in the exenatide group and 29 patients in the placebo group.

136 92 participants in the exenatide group and 96 in the placebo group had at least

137 interval [CI] = 3.0 to 9.3, SD = 6.9) in the exenatide group and by 13 3 points (95% CI = 9.2 to 17.3

138 .4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0

139 Six serious adverse events occurred in the exenatide group and two in the placebo group, although n

140 [4%]), which occurred less frequently in the exenatide group and with decreasing incidence over time

141 ed by 1.0 points (95% CI -2.6 to 0.7) in the exenatide group and worsened by 2.1 points (-0.6 to 4.8)

142 Nine (9%) participants in the exenatide group had at least one serious adverse event c

143 ocardial area at risk the data points of the exenatide group lay significantly lower than for the pla

144 Single-blinded rating of the exenatide group suggested clinically relevant improvemen

145 ean HbA1c change was -1.01% (SE 0.07) in the exenatide group versus -0.81% (0.07) in the glargine gro

146 irst, plus recurrent, HHF was reduced in the exenatide group versus placebo (HR, 0.82 [95% CI, 0.68-0

147 ] in the liraglutide group vs 43 [9%] in the exenatide group), diarrhoea (59 [13%] vs 28 [6%]), and v

148 gliflozin group, -1.6% (-1.8 to -1.4) in the exenatide group, and -1.4% (-1.6 to -1.2) in the dapagli

149 ozin group, 124 (54%) of 230 patients in the exenatide group, and 121 (52%) of 233 patients in the da

150 ed) by a mean of 5.7 points (SD 11.2) in the exenatide group, and by 4.5 points (SD 11.4) points in t

151 ese events did decrease after week 26 in the exenatide group.

152 INTERPRETATION: Exenatide had positive effects on practically defined of

153 TEN to the exenatide peptide should increase exenatide half-life in humans from 2.4 h to a projected

154 raglutide), SUSTAIN-6 (semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (dula

155 Exenatide has been demonstrated to be cardioprotective a

156 7; 95% CI: 0.79-1.19), or liraglutide versus exenatide (HR: 1.08; 95% CI: 0.83-1.38), nor were differ

157 Exenatide improved fasting and postprandial lipidomic pr

158 old half-life extension of the 39-aa peptide exenatide in rats, and a noncirculating s.c. hydrogel co

159 mployed to evaluate the anti-AF potential of exenatide in rats.

160 analysis study was to evaluate the effect of exenatide in relation to system delay, defined as time f

161 ffects of the glucagon-like peptide-1 analog exenatide in resuscitated OHCA patients.

162 e safety, efficacy, and metabolic effects of exenatide in subjects with type 1 diabetes mellitus and

163 nt studies have been published on the use of exenatide in the management of pediatric obesity and new

164 Adverse events of exenatide included nausea, diarrhea, vomiting, headache,

165 Exenatide increased CMRglu in areas of the brain related

166 Intravenous exenatide increased fasting EF, and exendin-9 abolished

167 Exenatide increased Fos-LI dose-dependently in the myent

168 Once-weekly exenatide increased heart rate compared with albiglutide

169 Subcutaneous exenatide increased postprandial EF independent of reduc

170 Use of sitagliptin or exenatide increased the odds ratio for reported pancreat

171 , reducing hyperinsulinemia to basal levels, exenatide-increased total glucose turnover was completel

172 ury model, a single intravenous injection of exenatide inhibited thrombus formation in normoglycemic

173 ke peptide (GLP-1) and its receptor agonist, Exenatide, inhibited palmitate-mediated caspase 3 activa

174 These findings demonstrate that exenatide inhibits I(Kv1.5) and I(Nav1.5)in vitro and re

175 n, pretreatment with exendin (9-39) prior to exenatide injection blocked the activation in both locat

176 ), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls.

177 Adding twice-daily exenatide injections improved glycemic control without i

178 present article presents the results of the exenatide intervention.

179 Exenatide is a synthetic agonist of the glucagon-like pe

180 Exenatide is a type 2 diabetes treatment that has been s

181 Our findings suggest that exenatide is safe and well tolerated.

182 Efficacy of once-weekly exenatide is sustained for 3 years.

183 tinuous subcutaneous infusion of the GLP-1RA exenatide (ITCA 650) is unknown.

184 1 (GLP-1) receptor via the antidiabetic drug exenatide led to improvements in both ERK and AKT signal

185 Both once daily liraglutide and once weekly exenatide led to improvements in glycaemic control, with

186 Both once daily liraglutide and once weekly exenatide led to improvements in glycaemic control, with

187 with PT320 producing continuous therapeutic Exenatide levels and more rapidly reaching a steady-stat

188 , reached and maintained steady-state plasma Exenatide levels more rapidly, without dipping to a sub-

189 c exposure increased across PT320 doses, and Exenatide levels were maintained above the therapeutic t

190 in) and GLP-1 receptor agonist (dulaglutide, exenatide, liraglutide, semaglutide) classes.

191 Agents such as exenatide, lixisenatide, and liraglutide have demonstrat

192 /kg/min) and exenatide:glucagon co-infusion (exenatide loading dose 50 ng/min for 30 min then 25 ng/m

193 -matched oral placebo, or dapagliflozin with exenatide-matched placebo injections.

194 Activation of the enteric neurons by exenatide may be part of the pathway by which this pepti

195 Transport of insulin, calcitonin, and exenatide measured at different loading concentrations s

196 of hyperglycemia versus hyperinsulinemia in exenatide-mediated glucose disposal was studied.

197 Only 4 drugs (brain natriuretic peptide, exenatide, metoprolol, and esmolol) stand unchallenged t

198 paring patients who initiated treatment with exenatide (n = 14 076, median follow-up 969 days; interq

199 ility, of whom 194 were randomly assigned to exenatide (n=97) or placebo (n=97).

200 -IV inhibitors were given 6 months GLP-1 RA (exenatide, n = 19; liraglutide, n = 6).

201 kidney 293 cells and studied the effects of exenatide on action potential (AP) and other cardiac ion

202 effects of a single injection of the GLP-1RA exenatide on cerebral and peripheral glucose metabolism

203 ng system was used to explore the effects of exenatide on electrical properties and AF activity in is

204 lamp technique to investigate the effects of exenatide on hKv1.5 and hNav1.5 channels expressed in hu

205 tudy determined the effect of GLP-1R agonist exenatide on postprandial EF in type 2 diabetes and the

206 randomly assigned to receive: 2 mg injected exenatide once weekly plus oral placebo once daily; 100

207 Addition of exenatide once weekly to metformin achieved this goal mo

208 In DURATION-3, exenatide once weekly was compared with insulin glargine

209 We compared the efficacy and safety of exenatide once weekly with liraglutide once daily in pat

210 e and the SGLT2 inhibitor dapagliflozin with exenatide or dapagliflozin alone in patients with type 2

211 Furthermore, Exenatide or forskolin reversed the inhibition by diazox

212 ients were randomized to receive intravenous exenatide or placebo before percutaneous coronary interv

213 ow 0/1 were randomly assigned to intravenous exenatide or placebo continuous infusion.

214 e intervention was an infusion of 17.4 ug of exenatide or placebo during cardiopulmonary bypass and t

215 s with type 2 diabetes received subcutaneous exenatide or placebo for 11 days and EF, and glucose and

216 Patients treated with exenatide or placebo had similar rates of MACE and LEA,

217 on counseling and were equally randomized to exenatide or placebo injection, twice per day.

218 F and papilloedema) who receive subcutaneous exenatide or placebo.

219 caling suggests that a fusion of XTEN to the exenatide peptide should increase exenatide half-life in

220 we randomly assigned 695 patients to receive exenatide plus dapagliflozin (n=231), exenatide alone (n

221 HbA1c was -2.0% (95% CI -2.1 to -1.8) in the exenatide plus dapagliflozin group, -1.6% (-1.8 to -1.4)

222 recorded in 131 (57%) of 231 patients in the exenatide plus dapagliflozin group, 124 (54%) of 230 pat

223 Exenatide plus dapagliflozin significantly reduced HbA1c

224 Exenatide plus dapagliflozin was significantly superior

225 concentrations of cAMP produced by GLP-1 and Exenatide preferentially activate the PKA pathway, where

226 Exenatide prevented AF incidence and duration in rat hea

227 With hyperinsulinemia and hyperglycemia, exenatide produced a significant increase in total gluco

228 Furthermore, exenatide prolonged AP duration and suppressed the susta

229 Thirteen exenatide recipients and 1 placebo recipient discontinue

230 112 of 138 exenatide recipients and 101 of 123 placebo recipients c

231 ing medications, and HbA(c) levels, and more exenatide recipients than placebo recipients withdrew be

232 Exenatide recovered characteristic spreading depolarizat

233 Treatment with exenatide reduced HbA(1c) (least square mean -1.5%, 95%

234 Exenatide reduced ICP, improving algetic thresholds and

235 Exenatide reduced RaO0-60 min (4.6 +/- 1.4 vs. 13.1 +/-

236 All doses of exenatide reduced sucrose intake following the 20 min ti

237 of this work is to test the hypothesis that exenatide reduces food intake and activates the enteric

238 ing glucagon-like peptide 1 receptor agonist exenatide reduces postprandial glycemia, partly by slowi

239 In contrast, Exenatide release from Bydureon exhibited a biphasic pro

240 Exenatide release from PT320 exhibited a triphasic pharm

241 Stability of exenatide remaining inside microspheres was evaluated by

242 Exenatide represents a major new avenue for investigatio

243 delay </=132 minutes (n=74), treatment with exenatide resulted in a smaller infarct size (9 grams [i

244 Treatment with exenatide resulted in increased salvage index both among

245 Exenatide reversibly suppressed I(Kv1.5) with IC(50) of

246 GLP-1) receptor agonists (e.g., liraglutide, exenatide, semaglutide).

247 -1 RAs were used (lixisenatide, liraglutide, exenatide, semaglutide, efpeglenatide, dulaglutide, albi

248 Exenatide significantly and meaningfully lowered intracr

249 licited a cAMP response in MEG-01 cells, and exenatide significantly inhibited thrombin-, ADP-, and c

250 suppressed lipolysis equal to baseline, but exenatide significantly lowered free fatty acid clearanc

251 Exenatide significantly lowered ICP [exenatide: 9.74 (6.

252 secondary peak at 5 days, and achievement of Exenatide steady-state plasma levels from day 10-28.

253 ducing systemic hyperglycemia to euglycemia, exenatide still increased total glucose turnover by appr

254 We aimed to investigate whether exenatide stimulates glucose turnover directly in insuli

255 ment with the glucagon-like peptide-1 analog exenatide, streptozotocin injection, partial pancreatect

256 EXSCEL (Exenatide Study of Cardiovascular Event Lowering) assess

257 for heart failure (HHF) in the EXSCEL study (Exenatide Study of Cardiovascular Event Lowering), with

258 abetes mellitus and PAD in the EXSCEL trial (Exenatide Study of Cardiovascular Event Lowering).

259 reversed the protective effects of GLP-1 and Exenatide, suggesting that PKA may play a role in the pr

260 -1 receptor agonists were more frequent with exenatide than glargine (nausea: 36 [15%] of 233 patient

261 d constipation (10% vs. 2%) were higher with exenatide than with placebo.

262 lin concentrations were initially lower with exenatide than with saline and subsequently higher.

263 n, RNase H that actively hydrolyzed RNA, and exenatide that is a commercial therapeutic peptide.

264 In contrast, subjects on exenatide therapy had significantly higher HSQ 2.0 score

265 to be a risk associated with sitagliptin or exenatide therapy in humans.

266 PAM (S)-9b potentiated low-dose exenatide to augment insulin secretion in primary mouse

267 Acute administration of exenatide to comatose patients in the intensive care uni

268 e combination of electrostatic adsorption of exenatide to the membrane surface and its self-associati

269 effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes

270 Exenatide total exposure, evaluated from the area under

271 Exenatide-treated patients had a mean improvement at 12

272 Thus, we investigated how exenatide treatment changes lipid metabolism and composi

273 Also, cardioprotection by exenatide treatment is independent of glucose levels at

274 In this post hoc analysis, exenatide treatment was associated with a 30% decrease i

275 r improvements in glycaemic control than did exenatide twice a day, and was generally better tolerate

276 Exenatide usage had a positive effect whereas single isl

277 [HR]) of composite treatment for DME or PDR: exenatide versus dulaglutide (HR 0.90; 95% confidence in

278 ptin, and -0.3% (-0.6 to -0.1, p=0.0165) for exenatide versus pioglitazone.

279 Exenatide versus placebo decreased food intake and food-

280 with rates of MACE, LEA, and the effects of exenatide versus placebo in patients with and without PA

281 literature-derived risk reductions, but the exenatide versus placebo MACE effect size and statistica

282 ere no differences in MACE or LEA rates with exenatide versus placebo.

283 re -0.6% (95% CI -0.9 to -0.4, p<0.0001) for exenatide versus sitagliptin, and -0.3% (-0.6 to -0.1, p

284 ups had slight weight loss (-5.5% vs. -1.9%, exenatide vs. control; P = 0.052).

285 ificant proteins changed differentially with exenatide vs. placebo therapy.

286 Exenatide was associated with positive effects on partic

287 -down ECD experiment showed that the Asp9 in exenatide was converted to isoAsp9 to form the unknown i

288 Decreased RaO0-60 min after exenatide was inversely correlated to CMRglu.

289 hours after admission in patients receiving exenatide was lower than that in patients receiving plac

290 Exenatide was tolerated in this patient population after

291 Exenatide was well tolerated, although weight loss was c

292 Although antithrombotic effects of exenatide were partly lost in mice transplanted with bon

293 The antidiabetic drugs sitagliptin and exenatide, which inhibit GLP-1 breakdown and stimulate G

294 once-daily dapagliflozin 10 mg oral tablets, exenatide with dapagliflozin-matched oral placebo, or da

295 les enabled the oral delivery of insulin and exenatide, with 10 U kg(-1) orally delivered insulin sus

296 administration of the GLP-1 receptor agonist exenatide, with or without prior GLP-1 receptor blockade

297 had EF measured before and after intravenous exenatide, with or without the GLP-1R antagonist exendin

298 We confirmed the biological activity of the exenatide-XTEN fusion in mice.